A
pharmaceutical company in the Northeast has offered 2:1 matching dollars to
fund research on a kinase inhibitor they make which our lab believes will be of
benefit to patients with alveolar rhabdomyosarcoma. The pharmaceutical company is willing to contribute up to $84,000
to match donations from the community of up to $42,000.
This particular drug (kinase inhibitor) has a
good rationale for being important exclusively in the alveolar subtype of
rhabdomyosarcoma, and it is rare that we find a partner in industry willing to
advance a drug just for alveolar rhabdomyosarcoma to the clinic. The
basic science studies we would do (preclinical studies) are the prelude to
clinical trial studies that the pharmaceutical company would pay for in full
(usually a >$2M investment on their part).
For more information, please email Charles at keller@ohsu.edu .
